X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

To Aid Keytruda And Gardasil, Merck Expands Singapore Hub

Content Team by Content Team
8th October 2022
in Facilities & Operation, News

Merck & Co. broke ground on a plant to produce next-generation inhalers on October 5th and rolled out a packaging facility in Singapore to serve its top-selling cancer medication and vaccine.

The company’s five-year investment plan for its Asia-Pacific regional headquarters in Singapore calls for up to $500 million in new infrastructure. A semi-automated vial packaging line for Merck’s cancer treatment Keytruda, in addition to three automated syringe packaging lines for its HPV vaccination Gardasil, will be located at the first site. Since 2021, Keytruda vials have been filled at Merck’s 72-acre manufacturing facility in southwest Singapore since 2021. The addition includes a quality control lab, refrigerated storage, and secondary packing.

More than a third of Merck’s overall sales in the second quarter ($5.3 billion) came from the company’s best-selling drug, Keytruda. With sales of $1.7 billion during the same period, Gardasil came in second.

When it opens in 2026, the inhaler factory will produce next-generation inhalation devices for controlled administration of medicines, according to Merck, who omitted to provide more information.

Although Merck doesn’t currently sell many inhalation medications, the company is working on a Phase 2/3 trial for an aerosol medication for pulmonary arterial hypertension. The corporation intends to grow its cardiovascular medication business over the next ten years, and that treatment is a component of that ambition.

With the additional facilities, Merck expects to create about 100 positions, bringing its total workforce in Singapore to more than 1,800. Since it started doing business there in 1997, Merck has committed $2 billion to the city-state in Southeast Asia.

Less than 3% of the company’s five-year $20 billion capital spending strategy, which also includes programmes supporting oncology, vaccines, and animal health products, is represented by the $500 million investment. Merck invested $4.4 billion in capital projects worldwide last year, $2.8 billion of which were in the United States.

According to Fernando Otero, associate vice president for MSD Production in Singapore, the business is dedicated to Singapore as a strategic node in their company’s worldwide manufacturing network with a focus on medicines for cancer, chronic diseases, and vaccines.

Previous Post

Vaccination Partnership Formed Between Ziphius And UZ Ghent

Next Post

OSD Contract Manufacturing Sector Valued At $54.7bn By 2030

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

OSD Contract Manufacturing Sector Valued At $54.7bn By 2030

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In